Compare PROP & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PROP | BOLD |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.1M | 60.8M |
| IPO Year | 2008 | 2024 |
| Metric | PROP | BOLD |
|---|---|---|
| Price | $0.42 | $2.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $6.75 | $4.00 |
| AVG Volume (30 Days) | ★ 1.6M | 83.1K |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 49.06 | 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,939,000.00 | N/A |
| Revenue This Year | $81.83 | N/A |
| Revenue Next Year | $18.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 413.59 | N/A |
| 52 Week Low | $0.38 | $0.96 |
| 52 Week High | $2.55 | $3.16 |
| Indicator | PROP | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 35.56 | 48.14 |
| Support Level | N/A | $2.74 |
| Resistance Level | $0.59 | $2.97 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 19.28 | 16.67 |
Prairie Operating Co is an independent oil and natural gas company focused on the acquisition and development of crude oil, natural gas, and natural gas liquids (NGLs). Its assets and operations are located in the oil region of rural Weld County, Colorado, within the Denver-Julesburg Basin in Colorado (the DJ Basin). The company generates maximum revenue from crude oil sales, and the rest from the sale of natural gas and natural gas liquids.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.